Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance

Rheumatology (Oxford). 2008 Feb;47(2):119-20. doi: 10.1093/rheumatology/kem294.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adalimumab
  • Anti-Inflammatory Agents, Non-Steroidal / economics
  • Anti-Inflammatory Agents, Non-Steroidal / standards
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Canada
  • Cost-Benefit Analysis
  • Etanercept
  • Humans
  • Immunoglobulin G / economics*
  • Immunoglobulin G / therapeutic use*
  • Quality of Life
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Spondylitis, Ankylosing / drug therapy*
  • Spondylitis, Ankylosing / economics*
  • State Medicine
  • United Kingdom

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Adalimumab
  • Etanercept